These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 34515171)

  • 1. Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study.
    Hatanaka T; Kakizaki S; Nagashima T; Namikawa M; Ueno T; Tojima H; Takizawa D; Naganuma A; Arai H; Harimoto N; Shirabe K; Uraoka T
    Oncology; 2021; 99(10):641-651. PubMed ID: 34515171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study.
    Chon YE; Kim DY; Kim MN; Kim BK; Kim SU; Park JY; Ahn SH; Ha Y; Lee JH; Lee KS; Kang B; Kim JS; Chon HJ; Kim DY
    Clin Mol Hepatol; 2024 Jul; 30(3):345-359. PubMed ID: 38468561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).
    Kobayashi K; Ogasawara S; Itobayashi E; Okubo T; Itokawa N; Nakamura K; Moriguchi M; Watanabe S; Ikeda M; Kuroda H; Kawaoka T; Hiraoka A; Yasui Y; Kuzuya T; Sato R; Kanzaki H; Koroki K; Inoue M; Nakamura M; Kiyono S; Kanogawa N; Kondo T; Nakamoto S; Ozawa Y; Tsuchiya K; Atsukawa M; Aikata H; Aramaki T; Oka S; Morimoto N; Kurosaki M; Itoh Y; Izumi N; Kato N
    Invest New Drugs; 2024 Aug; 42(4):394-404. PubMed ID: 38842657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta‑analysis.
    Zhu G; Zeng L; Yang L; Zhang X; Tang J; Pan Y; Li B; Chen M; Wu T
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1425-1434. PubMed ID: 38907884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Lu J; Lin X; Teng H; Zheng Y
    J Clin Pharmacol; 2024 Jun; 64(6):643-651. PubMed ID: 38311835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
    Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma.
    Kim HD; Park YG; Kim S; Kim KP; Park SR; Ryu MH; Ryoo BY; Yoo C
    Hepatol Int; 2024 Jun; 18(3):973-983. PubMed ID: 38214792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis.
    Changez MIK; Khan M; Uzair M; Tahir MF; Mohsin M; Hussain AF; Saqib V; Molani MK; Ahmed AH; Khalid S
    J Gastrointest Cancer; 2024 Mar; 55(1):467-481. PubMed ID: 38095799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab.
    Rimini M; Montes M; Amadeo E; Vitiello F; Kudo M; Tada T; Suda G; Shimose S; Lonardi S; Finkelmeier F; Salani F; Antonuzzo L; Marra F; Iavarone M; Cabibbo G; Foschi FG; Silletta M; Sacco R; Rapposelli IG; Scartozzi M; Nicoletta P; Aldrighetti L; Persano M; Camera S; Rossari F; Foti S; Kumada T; Hiraoka A; Iwamoto H; Rizzato MD; Himmelsbach V; Masi G; Corradi M; Celsa C; Fabio C; Frassineti GL; Cascinu S; Casadei-Gardini A; Presa J
    Sci Rep; 2024 Aug; 14(1):20200. PubMed ID: 39215078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of hepatocellular carcinoma patients treated in the lenvatinib and immunotherapy era (2018-2021) compared to the sorafenib era (2008-2018).
    Lim CA; Amaro CP; Ding PQ; Cheung WY; Tam VC
    Cancer Med; 2024 Jul; 13(13):e7415. PubMed ID: 38953381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib.
    Zhang L; Yang H; Ning S; Wu Z; Wang D; Liang H; Wang C; Chang X
    Cancer Med; 2024 Jun; 13(12):e7410. PubMed ID: 38923354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
    Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
    ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
    Finn RS; Ikeda M; Zhu AX; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Mody K; Llovet JM
    J Clin Oncol; 2020 Sep; 38(26):2960-2970. PubMed ID: 32716739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
    Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
    PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
    Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
    J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinoma.
    Praktiknjo M; Pena Solano AS; Sadeghlar F; Welchowski T; Schmid M; Möhring C; Zhou T; Mahn R; Monin MB; Meyer C; Feldmann G; Brossart P; van Beekum C; Semaan A; Matthaei H; Manekeller S; Sprinkart AM; Nowak S; Luetkens J; Kalff JC; Strassburg CP; González-Carmona MA
    Sci Rep; 2024 Sep; 14(1):22146. PubMed ID: 39333610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
    Takahashi A; Moriguchi M; Seko Y; Ishikawa H; Yo T; Kimura H; Fujii H; Shima T; Mitsumoto Y; Ishiba H; Takashima H; Nagao Y; Jo M; Arai M; Hara T; Okajima A; Muramatsu A; Morita A; Yoshinami N; Nakajima T; Mitsuyoshi H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y
    Anticancer Res; 2019 Sep; 39(9):5149-5156. PubMed ID: 31519627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
    Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.